VERAXA Biotech AG (NASDAQ: VRXA) has appointed Dr. Christoph Erkel as Chief Scientific Officer, reinforcing its commitment to advancing the proprietary BiTAC(R) technology platform. The move comes as the company prepares its lead oncology programs for clinical development, with recent regulatory feedback from Germany’s Paul-Ehrlich-Institute providing clarity for the BiTAC(R)-TCE program.
Dr. Erkel, previously Vice President of Research & Development at VERAXA, brings extensive experience in antibody therapeutics. In his new role, he will lead scientific strategy across the BiTAC(R) platforms and broader oncology pipeline, which includes conditionally active T-cell engagers, bispecific ADCs, and other engineered antibody therapeutics. The company is building a diversified pipeline aimed at improving efficacy while reducing treatment-related toxicity.
Investors are closely watching companies developing next-generation immunotherapies. VERAXA’s BiTAC(R) technology is designed to overcome limitations of conventional T-cell engagers by incorporating conditional activation, potentially reducing off-tumor toxicity. The recent regulatory feedback from the Paul-Ehrlich-Institute is seen as a positive step toward clinical trials.
The appointment of Dr. Erkel strengthens VERAXA’s scientific leadership as it moves toward clinical development. The company has not disclosed a specific timeline for initiating trials but has indicated that it is accelerating efforts to advance product candidates. More details are available in the company’s newsroom at https://ibn.fm/VRXA.
VERAXA is part of a dynamic landscape of biotechnology companies focused on innovative cancer therapies. The company’s platform and pipeline represent a potential shift in how T-cell engagers are designed, with an emphasis on safety and efficacy. The scientific leadership change is expected to drive these efforts forward.
